CD274 and neoplasm: Lastly, we evaluated the frequency of putative biomarkers of response to immune-checkpoint inhibitors at metastatic sites, including PD-L1+ expression by IHC (SP142 antibody), high tumor mutation burden (TMB-High ≥ 10 mutations/ Mb), and mismatch repair protein deficiency/high microsatellite instability (dMMR/MSI-high) status.